Phase I clinical study of brentuximab vedotin (SGN-35) involving children with recurrent or refractory CD30-positive Hodgkin's lymphoma or systemic anaplastic large cell lymphoma: rationale, design and methods of BV-HLALCL study: study protocol.
Masahiro SekimizuAkihiro IguchiTetsuya MoriYuhki KogaAkiko KadaAkiko M SaitoKeizo HoribePublished in: BMC cancer (2018)
JMACCT ID: JMA-IIA00229 . Registered on 17 Nov 2015.